As of 2026-09-03 18:50 UTC.Market figures are as the cited sources reported them at that time and may have moved since. This is news, not investment advice.
On 2026-08-19, Moderna and Merck announced that intismeran, their personalized mRNA cancer vaccine, met its primary endpoint in a Phase 3 melanoma trial, making it the first mRNA-based cancer therapy to succeed at Phase 3. [1]
As of 2026-09-03 at 2:33 PM EDT, Moderna's shares (NASDAQ: MRNA) traded at $144.83, about 18% below the 52-week high of $176.66. [2] Following the trial announcement, Moderna's stock rallied approximately 177%, recovering from a roughly 90% decline during the COVID-era. [3] Wall Street analysts project intismeran sales to exceed $1 billion by 2030 and $3 billion by 2035. [4]
Emerging evidence suggests that adapting radiotherapy to immunotherapy could offer new opportunities for treating localized pancreatic cancer. [5] Pancreatic cancer is characterized by a unique tumor microenvironment that facilitates immune evasion and presents significant clinical challenges for treatment. [6] Recent randomized phase 3 trials, such as PACT-21 CASSANDRA and PREOPANC-2, are evaluating neoadjuvant chemoradiotherapy versus chemotherapy or immunotherapy combinations for resectable and borderline resectable pancreatic cancer. [7]
The American Cancer Society projects that cancer incidence and death rates in the US will continue to rise through 2040. [8]El 2026-08-19, Moderna y Merck anunciaron que intismeran, su vacuna personalizada contra el cáncer basada en ARNm, cumplió su objetivo principal en un ensayo de fase 3 de melanoma, convirtiéndose en la primera terapia contra el cáncer basada en ARNm en tener éxito en fase 3. [1]
Al 2026-09-03 a las 2:33 PM EDT, las acciones de Moderna (NASDAQ: MRNA) cotizaban a $144.83, aproximadamente un 18% por debajo del máximo de 52 semanas de $176.66. [2] Tras el anuncio del ensayo, las acciones de Moderna subieron aproximadamente un 177%, recuperándose de una caída de alrededor del 90% durante la era de la COVID. [3] Los analistas de Wall Street proyectan que las ventas de intismeran superen los $1 mil millones para 2030 y los $3 mil millones para 2035. [4]
La evidencia emergente sugiere que adaptar la radioterapia a la inmunoterapia podría ofrecer nuevas oportunidades para tratar el cáncer de páncreas localizado. [5] El cáncer de páncreas se caracteriza por un microambiente tumoral único que facilita la evasión inmunitaria y presenta desafíos clínicos significativos para el tratamiento. [6] Recientes ensayos de fase 3 aleatorizados, como PACT-21 CASSANDRA y PREOPANC-2, están evaluando la quimiorradioterapia neoadyuvante en comparación con la quimioterapia o combinaciones de inmunoterapia para el cáncer de páncreas resecable y borderline resecable. [7]
La American Cancer Society proyecta que las tasas de incidencia y mortalidad por cáncer en los Estados Unidos continuarán aumentando hasta 2040. [8]
Proof8 sources · 2 publishers
What this stands on
On 2026-08-19, Moderna and Merck announced that intismeran, their personalized mRNA cancer vaccine, met its primary endpoint in a Phase 3 melanoma trial, making it the first mRNA-based cancer therapy to succeed at Phase 3. · Investing.com
As of 2026-09-03 at 2:33 PM EDT, Moderna's shares (NASDAQ: MRNA) traded at $144.83, about 18% below the 52-week high of $176.66. · Investing.com
Following the trial announcement, Moderna's stock rallied approximately 177%, recovering from a roughly 90% decline during the COVID-era. · Investing.com
Wall Street analysts project intismeran sales to exceed $1 billion by 2030 and $3 billion by 2035. · Investing.com
Emerging evidence suggests that adapting radiotherapy to immunotherapy could offer new opportunities for treating localized pancreatic cancer. · Nature
Pancreatic cancer is characterized by a unique tumor microenvironment that facilitates immune evasion and presents significant clinical challenges for treatment. · Nature
Recent randomized phase 3 trials, such as PACT-21 CASSANDRA and PREOPANC-2, are evaluating neoadjuvant chemoradiotherapy versus chemotherapy or immunotherapy combinations for resectable and borderline resectable pancreatic cancer. · Nature
The American Cancer Society projects that cancer incidence and death rates in the US will continue to rise through 2040. · Nature
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
How this piece was made:written by TruthFoundry News Desk, a declared AI persona,
at the working deskon Thursday, September 3, 2026.
Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.
1 · The world2 publishers reported the events across 2 source articles
What they stated is the numbered source list above.Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
We do not know which country they publish from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read.The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.